## Retrovirology



Poster presentation

**Open Access** 

# Adherence in HIV-I infected children taking once daily HAART with Didanosine + Lamivudine + Efavirenz in West Africa. ANRS 12103 clinical trial

Jerôme Somé\*<sup>1</sup>, Boubacar Nacro<sup>1</sup>, Hervé Hien<sup>2</sup>, Hassane Tamboura<sup>1</sup>, Emmanuelle Zouré<sup>1</sup>, Serge Diagbouga<sup>2</sup>, Adama Ouiminga<sup>2</sup>, Aly Drabo<sup>2</sup>, Alain Hien<sup>1</sup>, Souleymane Yaméogo<sup>1</sup>, Philippe Van de Perre<sup>3</sup> and Philippe Msellati<sup>4</sup>

Address: ¹Service de Pédiatrie, CHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso, ²Centre Muraz, Bobo-Dioulasso, Burkina Faso, ³Laboratoire de bactériologie, CHU de Montpellier, Hôpital Arnaud de Villeneuve,, Montpellier, France and ⁴UMR 145, IRD, Centre de Recherche Cultures Santé Sociétés/IFEHA, Université Paul Cézanne, Aix en Provence, France

from Fifth Dominique Dormont International Conference. Mother-to-child transmitted viral diseases: from transmission to children care Paris, France. 26–28 March 2009

Published: 22 July 2009

Retrovirology 2009, 6(Suppl I):P17 doi:10.1186/1742-4690-6-S1-P17

This abstract is available from: http://www.retrovirology.com/content/6/S1/P17

© 2009 Somé et al; licensee BioMed Central Ltd.

#### **Objective**

Assess adherence and determine the reasons of poor adherence in HIV-1 infected children taking once-a-day paediatric HAART with DDI+3TC+EFV in Bobo-Dioulasso, Burkina Faso.

#### **Methods**

Fifty-two HIV-1 infected children were followed during a 12-month period of the II phase clinical trial. Adherence was assessed using monthly pill counts. A questionnaire was administered quarterly in order to investigate reasons of poor adherence.

### **Results**

During the 12 months of follow up, two children died. Seven became resistant and 118 questionnaires were administered. Only two caregivers declared missed takings the previous week, which was contrasting with the counting. The difficulties reported by the caregivers were related to the time slot, and the instruction to take the pills on an empty stomach, the length of the treatment, the ARV's form and palatability.

The adherence rate was 98% and 32% of the patients had always had an adherence rate  $\geq$  95%. The adherence was not correlated to the socio-demographic factors and to the immuno-virological response.

#### Conclusion

Good adherence of this once daily's treatment study. No association between adherence, the socio-demographic factors and the infection's markers.

<sup>\*</sup> Corresponding author